ESLA
Estrella Immunopharma, Inc. NASDAQ Listed Sep 14, 2021$0.47
-0.11%
vs $0.47
Mkt Cap $20.2M
52w Low $0.43
1.6% of range
52w High $3.15
50d MA $0.66
200d MA $1.08
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
0.0x
ROE
126.0%
P/FCF
-9.8x
RSI (14)
24.00
ATR (14)
$0.06
Beta
0.58
50d MA
$0.66
200d MA
$1.08
Avg Volume
37.3K
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
CIK (SEC)
Phone
510 318 9098
5858 Horton Street · EmeryVille, CA 94608 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | AMC | -0.18 | -0.02 | +91.0% | 1.08 | +0.9% | +1.9% | -5.5% | -1.9% | -4.4% | +0.5% | — |
| Nov 12, 2025 | AMC | -0.19 | -0.13 | +30.3% | 2.10 | +3.3% | +4.8% | +3.2% | -18.1% | -2.2% | -3.8% | — |
| Aug 11, 2025 | AMC | -0.07 | -0.15 | -114.3% | 0.86 | -1.7% | +0.0% | -1.8% | +1.3% | +5.8% | +1.0% | — |
| May 14, 2025 | AMC | -0.11 | -0.06 | +45.5% | 0.99 | -0.3% | -5.0% | +2.0% | +2.2% | -0.1% | +3.1% | — |
| Feb 15, 2025 | AMC | -0.12 | -0.03 | +76.2% | — | — | — | — | — | — | — | — |
| Nov 14, 2024 | AMC | — | -0.09 | — | 0.84 | -6.0% | +6.0% | -0.0% | -4.4% | +8.2% | -3.3% | — |
| Sep 27, 2024 | AMC | — | -0.13 | — | 1.19 | -2.5% | -2.5% | +10.3% | -3.1% | -10.5% | +3.6% | — |
| May 14, 2024 | AMC | — | -0.01 | — | 1.05 | +7.6% | +2.9% | -2.8% | -3.8% | +4.0% | +0.0% | — |
| Feb 14, 2024 | AMC | — | -0.03 | — | 1.08 | +4.6% | +0.9% | +0.9% | -3.6% | -1.9% | -2.9% | — |
| Sep 30, 2023 | AMC | — | -1.78 | — | — | — | — | — | — | — | — | — |
| Jun 29, 2023 | AMC | — | -0.03 | — | 10.81 | +0.4% | +0.3% | +0.5% | +0.0% | +0.0% | +0.1% | — |
| Mar 30, 2023 | AMC | — | -0.03 | — | 10.58 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 9 | D. Boral Capital | Maintains | Buy → Buy | — | $1.45 | $1.34 | -7.6% | -1.4% | -3.5% | -5.8% | -5.4% | +2.4% |
| Jan 28 | D. Boral Capital | Maintains | Buy → Buy | — | $1.07 | $1.09 | +1.9% | -0.9% | +1.9% | +3.7% | -2.7% | +7.3% |
| Nov 3 | D. Boral Capital | Maintains | Buy → Buy | — | $2.42 | $2.43 | +0.4% | +26.0% | -24.9% | +11.8% | +7.8% | +6.2% |
| Aug 12 | D. Boral Capital | Maintains | Buy → Buy | — | $0.86 | $0.85 | -1.7% | +0.0% | -1.8% | +1.3% | +5.8% | +1.0% |
| Jun 3 | D. Boral Capital | Maintains | Buy → Buy | — | $0.97 | $1.10 | +13.4% | -14.0% | +18.7% | +7.1% | +0.9% | -7.6% |
| May 29 | D. Boral Capital | Maintains | Buy → Buy | — | $0.97 | $0.97 | +0.0% | +5.2% | -1.0% | -4.0% | -14.0% | +18.7% |
| Feb 21 | D. Boral Capital | Maintains | Buy → Buy | — | $1.49 | $1.69 | +13.4% | -0.7% | -10.8% | -12.1% | -5.2% | -12.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Oct 7, 2025 | Xu JiandongOff | Chief Financial Officer | Buy | 1,000 | $1.33 | $1K | 265,488 | +11.56% | -7.80% |
| Sep 22, 2025 | Xu JiandongOff | Chief Financial Officer | Buy | 1,000 | $1.16 | $1K | 16,700 | +11.56% | -7.80% |
| Sep 11, 2025 | Xu JiandongOff | Chief Financial Officer | Buy | 100 | $1.04 | $104 | 264,588 | +11.56% | -7.80% |
Institutional (13F) — Top 11
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 416,852 | $434K | Added | Jun 2026 |
| 2 | Wells Fargo & Company/mn | 264,388 | $280K | New | Mar 2026 |
| 3 | Blackrock, Inc. | 52,033 | $54K | New | Jun 2026 |
| 4 | Renaissance Technologies Llc | 39,100 | $41K | Reduced | Jun 2026 |
| 5 | Morgan Stanley | 22,194 | $35K | New | Dec 2025 |
| 6 | Northern Trust Corp | 19,624 | $21K | — | Mar 2026 |
| 7 | Jane Street Group, Llc | 10,441 | $16K | New | Dec 2025 |
| 8 | Ubs Group Ag | 15,079 | $16K | Added | Mar 2026 |
| 9 | Royal Bank Of Canada | 6,600 | $7K | — | Mar 2026 |
| 10 | Wolverine Asset Management Llc | 468 | $496 | New | Mar 2026 |
| 11 | Caitong International Asset Management Co., Ltd | 2 | $2 | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 62,562 | $76K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 37,765 | $40K | Mar 2026 |
| 3 | Fidelity Series Total Market Index Fund | 27,548 | $30K | May 2026 |
| 4 | Fidelity Total Market Index Fund | 16,762 | $18K | May 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 1,582 | $2K | Feb 2026 |
Valuation
Market Cap
$20.2M
Enterprise Value
$16.1M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.11x
P/B
—
P/S
—
P/FCF
-9.79x
EV/EBITDA
—
Shares Out
36.8M
Financials (TTM)
Revenue
$0
Net Income
-$10.0M
EBITDA
-$9.8M
Free Cash Flow
-$1.8M
Op Cash Flow
-$1.8M
EPS Basic
$-0.35
EPS Diluted
$-0.25
EPS Forward
$-0.39
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$3.2M
Total Liab.
$13.5M
Total Equity
-$10.4M
Cash
$1.4M
LT Debt
$0
Book Value/Sh
$-0.28
Debt/Equity
0.00x
Current Ratio
0.12
Quick Ratio
0.12
Returns & Growth
ROE
126.0%
ROA
-411.2%
ROIC
126.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
-40.0%
Price Returns
2W
-9.7%
1M
-31.2%
3M
-51.7%
6M
-54.8%
12M
-64.0%
Technicals
52W High
$3.15
52W Low
$0.43
50d MA
$0.66
200d MA
$1.08
RSI (14)
24.00
ATR (14)
$0.06
Beta
0.58
Avg Volume
37K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 7:41am
· Source: financialmodelingprep.com